2 ms·
> Multiple testing I imagine that the 'risk budget' would be divided up somehow. So a company can decide to use its risk budget on 10 small studies (potentia
by londons_explore 4y ago
> Multiple testing
I imagine that the 'risk budget' would be divided up somehow. So a company can decide to use its risk budget on 10 small studies (potentially of slightly different treatments) or one large study. They can mix-n-match and end one study early to reallocate the risk to another study to accelerate it, etc. Governments could allocate risk budgets to bio-tech companies or divide it per disease etc. The smaller initial risk budget of each smaller study decreases the chance of type I error, and the two effects could be designed to cancel.
> blinding
This approach doesn't prevent blinding. You're right that it makes it more complex. You could imagine a computer system (or independant human) that takes as input all the study results (ie. observations seen so far per patient), unblinds them, does predetermined statistical analysis, and outputs a number of new patients that may join the study today. That number could have a small amount of noise added to prevent "patient number 27 got a headache, and our patient limit fell, therefore patient 27 must be part of the treatment group".
> speed of enrollment of patients is limited by logistics
For the diseases that have the most human impact, this isn't the case. 50,000 people per day die of heart disease. I don't think any study will struggle to find a few hundred willing participants for a trial. For a disease with very few patients, the proposed scheme doesn't help, but also doesn't hurt.
- mcbain 4y agoRegarding blinding: I was part of a clinical trial (phase III, not the drug or cancer this article relates to). It couldn't be blinded - the side effects of the trial drug were too significant compared to just the standard of care which was the control. Also it would have been obvious during infusion, etc. There are many different ways to conduct research like this, of course there is no single perfect methodology.
- evandijk70 4y ago> Risk budget How does a smaller risk budget reduce the chance of type I error? Also, a lot of care would have to be taken that all smaller studies are pre-registered as well as their outcomes. > Unblinding In practice, things happen that were not foreseen in the predefined analysis plan. Still, that solution may work provided that the statistical issues were solved correctly. > speed of enrolment Patient groups are often very selected, and almost all studies struggle to find sufficient participants. This leads to delay for many studies, and 1 in 10 studies are even prematurely stopped solely because they cannot find enough participants [1]. [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843106/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843106/